Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 33 - 36
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s33
Publié en ligne 15 novembre 2005
  1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287 : 1308–20. [Google Scholar]
  2. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann Intern Med 2003; 138 : 338–46. [Google Scholar]
  3. Hagège A, Schwartz K, Desnos M, Carrier L. Genetic basis and genotype-phenotype relationships in familial hypertrophic cardiomyopathy. In: Maron BJ, ed. Diagnosis and management of hypertrophic cardiomyopathy. Cambridge USA: Blackwell Futura, 2004. [Google Scholar]
  4. Shah JS, Elliott PM. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr 2005; 94 (suppl): 11–4. [Google Scholar]
  5. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40 : 1668–74. [Google Scholar]
  6. Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001; 24 (suppl 2): 75–83. [Google Scholar]
  7. Nakao S, Takenaka T, Maeda M, et al. An Atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333 : 288–93. [Google Scholar]
  8. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105 : 1407–11. [Google Scholar]
  9. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110 : 1047–53. [Google Scholar]
  10. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy ? Heart 2003; 89 : 929–30. [Google Scholar]
  11. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352 : 362–72. [Google Scholar]
  12. Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107 : 1978–84 [Google Scholar]
  13. Nagueh SF, McFalls J, Meyer D, et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003; 108 : 395–8. [Google Scholar]
  14. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin Genet 2004; 66 : 158–65. [Google Scholar]
  15. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108 : 1299–301. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.